Aardvark Therapeutics (NASDAQ:AARD) announced on March 2, 2026, that it was pausing its Phase 3 Hunger Elimination of Reduction Objective (HERO) trial for its drug candidate ARD-101, which targets hyperphagia in patients with Prader-Willi Syndrome. This decision was prompted by serious safety concerns, specifically 'reversible cardiac observations.' Following the announcement, Aardvark's share price plummeted by 56%, leading to an investigation by Hagens Berman, a national shareholder rights firm. The firm is examining whether Aardvark misled investors regarding the drug's safety and efficacy, as well as its communications with the U.S. Food and Drug Administration (FDA). Aardvark had previously touted ARD-101 as a 'first-in-class' treatment with a strong safety profile. The firm is now urging investors who have incurred significant losses to come forward and assist in the investigation, which could potentially lead to legal action against Aardvark for any violations of federal securities laws.